Search

Home > GRACEcast Lung Cancer Video > Immunotherapy for Non-Squamous NSCLC: Should We be Using Biomarker Selection?
Podcast: GRACEcast Lung Cancer Video
Episode:

Immunotherapy for Non-Squamous NSCLC: Should We be Using Biomarker Selection?
Category: Science & Medicine
Duration: 00:10:45
Publish Date: 2015-06-18 14:00:00
Description:

The immune checkpoint inhibitor Opdivo (nivolumab) shows better efficacy than Taxotere (docetaxel) for advanced non-squamous NSCLC, but this was seen only in patients with PD-L1 protein expression on their tumor. Should we be using this as a biomarker?
Total Play: 0